Flexible Micro-Batch Scheduling: 500-Unit Launches on the Production Line
Big-batch CDMO economics don't fit a 500-unit launch. This playbook shows how the 0.5–5 L closed line schedules many small programs without sacrificing records..5–5 L scheduling with fast changeovers is the manufacturing answer.
01 · The problem
Emerging exosome brands ask a manufacturing question big-batch CDMOs cannot answer profitably: can I launch at 500 units, restock monthly, and change formats without redoing validation? Large-batch economics amortize over volume the brand doesn't have yet; the MOQ wall stops launches before they start. The 0.5–5 L line was built for exactly this question.
02 · Scientific rationale
The 0.5–5 L closed line's design variables are changeover speed and traceability: format changeovers (vial, tablet, mist) re-qualify within hours under the documented changeover SOP, every batch keeps full records, and utilization stays high across many small programs. Pilot-to-production runs on the same line: the pilot batch is the first production batch.
03 · Program documentation
Scheduling logic and changeover procedures are documented in TONGNIAN's internal process files [6].
Method anchors: [1] EV biology and cargo [2] MISEV2018 characterization [3] category evidence (review or registered study) [4] formulation and handling guidance [5] national measurement guideline (2026 No. 17) [6] internal protocol and case documentation.
04 · Product architecture
| Cadence | Volume | What it serves |
|---|---|---|
| Sample kits | 3–5 days | Channel trials and diligence |
| Pilot | 500 units | Launch and first sell-through |
| Production | 2,000+ units | Standard replenishment |
| Rush | 7 workdays | Emergency restock when a channel sells out mid-cycle |
05 · Process & QC
Programs are scheduled per cadence with fixed process parameters per format family; retain samples and batch records accompany every run. QC per the standard panel [2][5].
Fig. 1 — The scheduling cadence: samples, pilot, production, rush.
06 · Regulatory pathway: EU & US first
Scheduling is market-neutral; each program family carries its destination-market route (cosmetic, supplement, professional).
07 · Expected outcomes
- Pilot-volume launch: 500-unit pilots run on the same line, under the same records, as production.
- Channel-paced restock: monthly or quarterly replenishment matched to your sell-through.
- Traceability at every cadence: small batches ship with the same batch records and retain samples as large runs.
No claims beyond the destination-market framing — authority comes from documentation and batch measurement.
08 · Commercial framework
Sample kits in 3-5 days; pilot from 500 units; production from 2,000 units; standard lead 15 workdays - all indicative, quoted per request. White-label and program naming run through the OBM program.
Request a quote - Line fact-sheet per program page.
References
- Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.
- Théry C, et al. MISEV2018. J Extracell Vesicles. 2018;7(1):1535750.
- Cobetter. Exosomes Part I: Applications and Downstream Processing Overview. Technical review, 2025.
- Guideline for Exosome Particle Size and Concentration Measurement (2026 No. 17) — TONGNIAN, drafting organization.
- TONGNIAN internal process documentation — closed-line SOPs, QC panels, batch records (partner access under NDA).
Apply this playbook to your category
Submit your brand stage, target category, and target volume tier to receive specifications, MOQ, and lead-time quotes for the matching tier (quotation follows the tier structure).